HPTN 083‐02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study
Introduction HPTN 083 demonstrated the superiority of long‐acting cabotegravir (CAB‐LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) as pre‐exposure prophylaxis (PrEP) among cisgender men and transgender women who have sex with men (MSM/TGW). HPTN 083 provided the first op...
Saved in:
| Published in | Journal of the International AIDS Society Vol. 27; no. 5; pp. e26252 - n/a |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
John Wiley & Sons, Inc
01.05.2024
Wiley |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Introduction
HPTN 083 demonstrated the superiority of long‐acting cabotegravir (CAB‐LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) as pre‐exposure prophylaxis (PrEP) among cisgender men and transgender women who have sex with men (MSM/TGW). HPTN 083 provided the first opportunity to understand experiences with injectable PrEP in a clinical trial.
Methods
Participants from two US sites (Chicago, IL and Atlanta, GA) and one international site (Rio de Janeiro, Brazil) were purposively sampled for individual qualitative interviews (N = 40), between November 2019 and March 2020, to explore trial experiences, barriers to adherence and other factors that may have impacted study implementation or outcomes. The blinded phase ended early due to efficacy; this analysis includes interviews conducted prior to unblinding with three groups defined by adherence (i.e. injection visit attendance): adherent (n = 27), non‐adherent (n = 12) and early discontinuers (n = 1). Data were organized using NVivo software and analysed using content analysis.
Results
Participants (mean age: 27) were primarily cisgender MSM (90%) and Black/African American (60%). Reasons for trial enrolment and PrEP use included a preference for using HIV prevention medication versus treatment in the event of HIV acquisition; the ability to enhance health via study‐related education and services; access to a novel, convenient HIV prevention product at no cost; and contributing to MSM/TGW communities through research. Participants contrasted positive experiences with study staff with their routine clinical care, and emphasized increased scheduling flexibility, thorough communication, non‐judgemental counselling and open, affirming environments (e.g. compassion, less stigma) as adherence facilitators. Injection experiences were positive overall; some described early injection‐related anxiety, which abated with time and when given some measure of control (e.g. pre‐injection countdown), and minimal injection site discomfort. Some concerns and misperceptions about injectable PrEP were reported. Barriers to adherence, across all adherence categories, included structural factors (e.g. financial constraints, travel) and competing demands (e.g. work schedules).
Conclusions
Respondents viewed injectable PrEP trial participation as a positive experience and a means of enhancing wellbeing. Study site flexibility and affirming clinic environments, inclusive of non‐judgemental counselling, were key facilitators of adherence. To support injection persistence, interventions that address structural barriers and promote flexible means of injection delivery may be most effective. |
|---|---|
| AbstractList | HPTN 083 demonstrated the superiority of long‐acting cabotegravir (CAB‐LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) as pre‐exposure prophylaxis (PrEP) among cisgender men and transgender women who have sex with men (MSM/TGW). HPTN 083 provided the first opportunity to understand experiences with injectable PrEP in a clinical trial. Respondents viewed injectable PrEP trial participation as a positive experience and a means of enhancing wellbeing. Study site flexibility and affirming clinic environments, inclusive of non‐judgemental counselling, were key facilitators of adherence. To support injection persistence, interventions that address structural barriers and promote flexible means of injection delivery may be most effective. Introduction: HPTN 083 demonstrated the superiority of long‐acting cabotegravir (CAB‐LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) as pre‐exposure prophylaxis (PrEP) among cisgender men and transgender women who have sex with men (MSM/TGW). HPTN 083 provided the first opportunity to understand experiences with injectable PrEP in a clinical trial. Methods: Participants from two US sites (Chicago, IL and Atlanta, GA) and one international site (Rio de Janeiro, Brazil) were purposively sampled for individual qualitative interviews (N = 40), between November 2019 and March 2020, to explore trial experiences, barriers to adherence and other factors that may have impacted study implementation or outcomes. The blinded phase ended early due to efficacy; this analysis includes interviews conducted prior to unblinding with three groups defined by adherence (i.e. injection visit attendance): adherent (n = 27), non‐adherent (n = 12) and early discontinuers (n = 1). Data were organized using NVivo software and analysed using content analysis. Results: Participants (mean age: 27) were primarily cisgender MSM (90%) and Black/African American (60%). Reasons for trial enrolment and PrEP use included a preference for using HIV prevention medication versus treatment in the event of HIV acquisition; the ability to enhance health via study‐related education and services; access to a novel, convenient HIV prevention product at no cost; and contributing to MSM/TGW communities through research. Participants contrasted positive experiences with study staff with their routine clinical care, and emphasized increased scheduling flexibility, thorough communication, non‐judgemental counselling and open, affirming environments (e.g. compassion, less stigma) as adherence facilitators. Injection experiences were positive overall; some described early injection‐related anxiety, which abated with time and when given some measure of control (e.g. pre‐injection countdown), and minimal injection site discomfort. Some concerns and misperceptions about injectable PrEP were reported. Barriers to adherence, across all adherence categories, included structural factors (e.g. financial constraints, travel) and competing demands (e.g. work schedules). Conclusions: Respondents viewed injectable PrEP trial participation as a positive experience and a means of enhancing wellbeing. Study site flexibility and affirming clinic environments, inclusive of non‐judgemental counselling, were key facilitators of adherence. To support injection persistence, interventions that address structural barriers and promote flexible means of injection delivery may be most effective. HPTN 083 demonstrated the superiority of long-acting cabotegravir (CAB-LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) as pre-exposure prophylaxis (PrEP) among cisgender men and transgender women who have sex with men (MSM/TGW). HPTN 083 provided the first opportunity to understand experiences with injectable PrEP in a clinical trial.INTRODUCTIONHPTN 083 demonstrated the superiority of long-acting cabotegravir (CAB-LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) as pre-exposure prophylaxis (PrEP) among cisgender men and transgender women who have sex with men (MSM/TGW). HPTN 083 provided the first opportunity to understand experiences with injectable PrEP in a clinical trial.Participants from two US sites (Chicago, IL and Atlanta, GA) and one international site (Rio de Janeiro, Brazil) were purposively sampled for individual qualitative interviews (N = 40), between November 2019 and March 2020, to explore trial experiences, barriers to adherence and other factors that may have impacted study implementation or outcomes. The blinded phase ended early due to efficacy; this analysis includes interviews conducted prior to unblinding with three groups defined by adherence (i.e. injection visit attendance): adherent (n = 27), non-adherent (n = 12) and early discontinuers (n = 1). Data were organized using NVivo software and analysed using content analysis.METHODSParticipants from two US sites (Chicago, IL and Atlanta, GA) and one international site (Rio de Janeiro, Brazil) were purposively sampled for individual qualitative interviews (N = 40), between November 2019 and March 2020, to explore trial experiences, barriers to adherence and other factors that may have impacted study implementation or outcomes. The blinded phase ended early due to efficacy; this analysis includes interviews conducted prior to unblinding with three groups defined by adherence (i.e. injection visit attendance): adherent (n = 27), non-adherent (n = 12) and early discontinuers (n = 1). Data were organized using NVivo software and analysed using content analysis.Participants (mean age: 27) were primarily cisgender MSM (90%) and Black/African American (60%). Reasons for trial enrolment and PrEP use included a preference for using HIV prevention medication versus treatment in the event of HIV acquisition; the ability to enhance health via study-related education and services; access to a novel, convenient HIV prevention product at no cost; and contributing to MSM/TGW communities through research. Participants contrasted positive experiences with study staff with their routine clinical care, and emphasized increased scheduling flexibility, thorough communication, non-judgemental counselling and open, affirming environments (e.g. compassion, less stigma) as adherence facilitators. Injection experiences were positive overall; some described early injection-related anxiety, which abated with time and when given some measure of control (e.g. pre-injection countdown), and minimal injection site discomfort. Some concerns and misperceptions about injectable PrEP were reported. Barriers to adherence, across all adherence categories, included structural factors (e.g. financial constraints, travel) and competing demands (e.g. work schedules).RESULTSParticipants (mean age: 27) were primarily cisgender MSM (90%) and Black/African American (60%). Reasons for trial enrolment and PrEP use included a preference for using HIV prevention medication versus treatment in the event of HIV acquisition; the ability to enhance health via study-related education and services; access to a novel, convenient HIV prevention product at no cost; and contributing to MSM/TGW communities through research. Participants contrasted positive experiences with study staff with their routine clinical care, and emphasized increased scheduling flexibility, thorough communication, non-judgemental counselling and open, affirming environments (e.g. compassion, less stigma) as adherence facilitators. Injection experiences were positive overall; some described early injection-related anxiety, which abated with time and when given some measure of control (e.g. pre-injection countdown), and minimal injection site discomfort. Some concerns and misperceptions about injectable PrEP were reported. Barriers to adherence, across all adherence categories, included structural factors (e.g. financial constraints, travel) and competing demands (e.g. work schedules).Respondents viewed injectable PrEP trial participation as a positive experience and a means of enhancing wellbeing. Study site flexibility and affirming clinic environments, inclusive of non-judgemental counselling, were key facilitators of adherence. To support injection persistence, interventions that address structural barriers and promote flexible means of injection delivery may be most effective.CONCLUSIONSRespondents viewed injectable PrEP trial participation as a positive experience and a means of enhancing wellbeing. Study site flexibility and affirming clinic environments, inclusive of non-judgemental counselling, were key facilitators of adherence. To support injection persistence, interventions that address structural barriers and promote flexible means of injection delivery may be most effective. HPTN 083 demonstrated the superiority of long-acting cabotegravir (CAB-LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) as pre-exposure prophylaxis (PrEP) among cisgender men and transgender women who have sex with men (MSM/TGW). HPTN 083 provided the first opportunity to understand experiences with injectable PrEP in a clinical trial. Participants from two US sites (Chicago, IL and Atlanta, GA) and one international site (Rio de Janeiro, Brazil) were purposively sampled for individual qualitative interviews (N = 40), between November 2019 and March 2020, to explore trial experiences, barriers to adherence and other factors that may have impacted study implementation or outcomes. The blinded phase ended early due to efficacy; this analysis includes interviews conducted prior to unblinding with three groups defined by adherence (i.e. injection visit attendance): adherent (n = 27), non-adherent (n = 12) and early discontinuers (n = 1). Data were organized using NVivo software and analysed using content analysis. Participants (mean age: 27) were primarily cisgender MSM (90%) and Black/African American (60%). Reasons for trial enrolment and PrEP use included a preference for using HIV prevention medication versus treatment in the event of HIV acquisition; the ability to enhance health via study-related education and services; access to a novel, convenient HIV prevention product at no cost; and contributing to MSM/TGW communities through research. Participants contrasted positive experiences with study staff with their routine clinical care, and emphasized increased scheduling flexibility, thorough communication, non-judgemental counselling and open, affirming environments (e.g. compassion, less stigma) as adherence facilitators. Injection experiences were positive overall; some described early injection-related anxiety, which abated with time and when given some measure of control (e.g. pre-injection countdown), and minimal injection site discomfort. Some concerns and misperceptions about injectable PrEP were reported. Barriers to adherence, across all adherence categories, included structural factors (e.g. financial constraints, travel) and competing demands (e.g. work schedules). Respondents viewed injectable PrEP trial participation as a positive experience and a means of enhancing wellbeing. Study site flexibility and affirming clinic environments, inclusive of non-judgemental counselling, were key facilitators of adherence. To support injection persistence, interventions that address structural barriers and promote flexible means of injection delivery may be most effective. Abstract Introduction HPTN 083 demonstrated the superiority of long‐acting cabotegravir (CAB‐LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) as pre‐exposure prophylaxis (PrEP) among cisgender men and transgender women who have sex with men (MSM/TGW). HPTN 083 provided the first opportunity to understand experiences with injectable PrEP in a clinical trial. Methods Participants from two US sites (Chicago, IL and Atlanta, GA) and one international site (Rio de Janeiro, Brazil) were purposively sampled for individual qualitative interviews (N = 40), between November 2019 and March 2020, to explore trial experiences, barriers to adherence and other factors that may have impacted study implementation or outcomes. The blinded phase ended early due to efficacy; this analysis includes interviews conducted prior to unblinding with three groups defined by adherence (i.e. injection visit attendance): adherent (n = 27), non‐adherent (n = 12) and early discontinuers (n = 1). Data were organized using NVivo software and analysed using content analysis. Results Participants (mean age: 27) were primarily cisgender MSM (90%) and Black/African American (60%). Reasons for trial enrolment and PrEP use included a preference for using HIV prevention medication versus treatment in the event of HIV acquisition; the ability to enhance health via study‐related education and services; access to a novel, convenient HIV prevention product at no cost; and contributing to MSM/TGW communities through research. Participants contrasted positive experiences with study staff with their routine clinical care, and emphasized increased scheduling flexibility, thorough communication, non‐judgemental counselling and open, affirming environments (e.g. compassion, less stigma) as adherence facilitators. Injection experiences were positive overall; some described early injection‐related anxiety, which abated with time and when given some measure of control (e.g. pre‐injection countdown), and minimal injection site discomfort. Some concerns and misperceptions about injectable PrEP were reported. Barriers to adherence, across all adherence categories, included structural factors (e.g. financial constraints, travel) and competing demands (e.g. work schedules). Conclusions Respondents viewed injectable PrEP trial participation as a positive experience and a means of enhancing wellbeing. Study site flexibility and affirming clinic environments, inclusive of non‐judgemental counselling, were key facilitators of adherence. To support injection persistence, interventions that address structural barriers and promote flexible means of injection delivery may be most effective. Introduction HPTN 083 demonstrated the superiority of long‐acting cabotegravir (CAB‐LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) as pre‐exposure prophylaxis (PrEP) among cisgender men and transgender women who have sex with men (MSM/TGW). HPTN 083 provided the first opportunity to understand experiences with injectable PrEP in a clinical trial. Methods Participants from two US sites (Chicago, IL and Atlanta, GA) and one international site (Rio de Janeiro, Brazil) were purposively sampled for individual qualitative interviews (N = 40), between November 2019 and March 2020, to explore trial experiences, barriers to adherence and other factors that may have impacted study implementation or outcomes. The blinded phase ended early due to efficacy; this analysis includes interviews conducted prior to unblinding with three groups defined by adherence (i.e. injection visit attendance): adherent (n = 27), non‐adherent (n = 12) and early discontinuers (n = 1). Data were organized using NVivo software and analysed using content analysis. Results Participants (mean age: 27) were primarily cisgender MSM (90%) and Black/African American (60%). Reasons for trial enrolment and PrEP use included a preference for using HIV prevention medication versus treatment in the event of HIV acquisition; the ability to enhance health via study‐related education and services; access to a novel, convenient HIV prevention product at no cost; and contributing to MSM/TGW communities through research. Participants contrasted positive experiences with study staff with their routine clinical care, and emphasized increased scheduling flexibility, thorough communication, non‐judgemental counselling and open, affirming environments (e.g. compassion, less stigma) as adherence facilitators. Injection experiences were positive overall; some described early injection‐related anxiety, which abated with time and when given some measure of control (e.g. pre‐injection countdown), and minimal injection site discomfort. Some concerns and misperceptions about injectable PrEP were reported. Barriers to adherence, across all adherence categories, included structural factors (e.g. financial constraints, travel) and competing demands (e.g. work schedules). Conclusions Respondents viewed injectable PrEP trial participation as a positive experience and a means of enhancing wellbeing. Study site flexibility and affirming clinic environments, inclusive of non‐judgemental counselling, were key facilitators of adherence. To support injection persistence, interventions that address structural barriers and promote flexible means of injection delivery may be most effective. IntroductionHPTN 083 demonstrated the superiority of long-acting cabotegravir (CAB-LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) as pre-exposure prophylaxis (PrEP) among cisgender men and transgender women who have sex with men (MSM/TGW). HPTN 083 provided the first opportunity to understand experiences with injectable PrEP in a clinical trial.MethodsParticipants from two US sites (Chicago, IL and Atlanta, GA) and one international site (Rio de Janeiro, Brazil) were purposively sampled for individual qualitative interviews (N = 40), between November 2019 and March 2020, to explore trial experiences, barriers to adherence and other factors that may have impacted study implementation or outcomes. The blinded phase ended early due to efficacy; this analysis includes interviews conducted prior to unblinding with three groups defined by adherence (i.e. injection visit attendance): adherent (n = 27), non-adherent (n = 12) and early discontinuers (n = 1). Data were organized using NVivo software and analysed using content analysis.ResultsParticipants (mean age: 27) were primarily cisgender MSM (90%) and Black/African American (60%). Reasons for trial enrolment and PrEP use included a preference for using HIV prevention medication versus treatment in the event of HIV acquisition; the ability to enhance health via study-related education and services; access to a novel, convenient HIV prevention product at no cost; and contributing to MSM/TGW communities through research. Participants contrasted positive experiences with study staff with their routine clinical care, and emphasized increased scheduling flexibility, thorough communication, non-judgemental counselling and open, affirming environments (e.g. compassion, less stigma) as adherence facilitators. Injection experiences were positive overall; some described early injection-related anxiety, which abated with time and when given some measure of control (e.g. pre-injection countdown), and minimal injection site discomfort. Some concerns and misperceptions about injectable PrEP were reported. Barriers to adherence, across all adherence categories, included structural factors (e.g. financial constraints, travel) and competing demands (e.g. work schedules).ConclusionsRespondents viewed injectable PrEP trial participation as a positive experience and a means of enhancing wellbeing. Study site flexibility and affirming clinic environments, inclusive of non-judgemental counselling, were key facilitators of adherence. To support injection persistence, interventions that address structural barriers and promote flexible means of injection delivery may be most effective. |
| Audience | Academic |
| Author | Singh, Yashna Kelley, Colleen F. Coelho, Lara E. Fields, Sheldon D. Sugarman, Jeremy Rice, Whitney Griffith, Sam Middelkoop, Keren Phanuphak, Nittaya Go, Vivian Goodman, Georgia R. Psaros, Christina Safren, Steven A. Clark, Jesse Landovitz, Raphael J. Rooney, James Oyedele, Temitope Adeyeye, Adeola Grinsztejn, Beatriz Rinehart, Alex R. McCauley, Marybeth Lee, Jasper S. |
| Author_xml | – sequence: 1 givenname: Christina orcidid: 0000-0002-0705-2239 surname: Psaros fullname: Psaros, Christina email: cpsaros@mgh.harvard.edu organization: Harvard Medical School – sequence: 2 givenname: Georgia R. orcidid: 0000-0002-9404-4455 surname: Goodman fullname: Goodman, Georgia R. organization: Brigham and Women's Hospital – sequence: 3 givenname: Jasper S. surname: Lee fullname: Lee, Jasper S. organization: Massachusetts General Hospital – sequence: 4 givenname: Whitney orcidid: 0000-0003-1749-023X surname: Rice fullname: Rice, Whitney organization: Emory University Rollins School of Public Health – sequence: 5 givenname: Colleen F. orcidid: 0000-0001-5611-0119 surname: Kelley fullname: Kelley, Colleen F. organization: Emory University School of Medicine – sequence: 6 givenname: Temitope surname: Oyedele fullname: Oyedele, Temitope organization: AstraZeneca Pharmaceuticals – sequence: 7 givenname: Lara E. orcidid: 0000-0001-7154-8151 surname: Coelho fullname: Coelho, Lara E. organization: Instituto Nacional de Infectologia Evandro Chagas‐Fiocruz – sequence: 8 givenname: Nittaya orcidid: 0000-0002-0036-3165 surname: Phanuphak fullname: Phanuphak, Nittaya organization: Chulalongkorn University – sequence: 9 givenname: Yashna surname: Singh fullname: Singh, Yashna organization: University of Cape Town – sequence: 10 givenname: Keren surname: Middelkoop fullname: Middelkoop, Keren organization: University of Cape Town – sequence: 11 givenname: Sam surname: Griffith fullname: Griffith, Sam organization: Family Health International 360 – sequence: 12 givenname: Marybeth surname: McCauley fullname: McCauley, Marybeth organization: Family Health International 360 – sequence: 13 givenname: James surname: Rooney fullname: Rooney, James organization: Gilead Sciences – sequence: 14 givenname: Alex R. surname: Rinehart fullname: Rinehart, Alex R. organization: ViiV Healthcare – sequence: 15 givenname: Jesse orcidid: 0000-0001-5862-6530 surname: Clark fullname: Clark, Jesse organization: University of California – sequence: 16 givenname: Vivian surname: Go fullname: Go, Vivian organization: University of North Carolina Gillings School of Global Public Health – sequence: 17 givenname: Jeremy orcidid: 0000-0001-7022-8332 surname: Sugarman fullname: Sugarman, Jeremy organization: Johns Hopkins University – sequence: 18 givenname: Sheldon D. surname: Fields fullname: Fields, Sheldon D. organization: The Pennsylvania State University – sequence: 19 givenname: Adeola surname: Adeyeye fullname: Adeyeye, Adeola organization: US Centers for Disease Control and Prevention – sequence: 20 givenname: Beatriz surname: Grinsztejn fullname: Grinsztejn, Beatriz organization: Instituto Nacional de Infectologia Evandro Chagas‐Fiocruz – sequence: 21 givenname: Raphael J. surname: Landovitz fullname: Landovitz, Raphael J. organization: University of California – sequence: 22 givenname: Steven A. orcidid: 0000-0002-0121-0806 surname: Safren fullname: Safren, Steven A. organization: University of Miami |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38783534$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u1DAQxyNURD_gwgOgSEgIIe3iz8ThtqoKXVTBHsrZcuzJrqOsXexEaG88As_Ik-BsSmlhhXzwaOY3f49n5jQ7ct5Blj3HaI4RIm9bq8icFISTR9kJLrmYkYKTo3v2cXYaY4tQQQSrnmTHVJSCcspOMnu5uv6UI0F_fv-ByLu8Ubr3IebWNd0ATlu3zpXZQEg25L1PgRZ0r-oO8lW4WOXKmTxAD6633qVocvzDxH4wu6fZ40Z1EZ7d3mfZl_cX1-eXs6vPH5bni6uZ5pyRGdYaEcwME02tCVOEGVNqoaluMDa6AQMVBcxJgUWjKKIlI5VOWbyEosYFPcuWk67xqpU3wW5V2EmvrNw7fFhLFXqrO5CV4JjUVFRAasZJqYxWmCPNUEUpL8qk9XrSugn-6wCxl1sbNXSdcuCHKCkqUgEVFSKhL_9CWz8El366p8qqoKL4Q61Vej812fdB6VFULsqqxFRwNmrNDlBrcBBUl2bf2OR-wM8P8OkY2Fp9MOHVvYQNqK7fRN8N4wzjQ_DNBOrgYwzQ3DUUIzkunxyXT-6XL8Evblsw1Fswd-jvbUsAnoBvqZ7df6Tkx-WCTKK_ANAM4E8 |
| Cites_doi | 10.1186/s12889-022-14134-4 10.1056/NEJMoa1202614 10.1016/j.jadohealth.2019.08.014 10.1007/s10461-022-03652-2 10.7861/clinmed.2021-0292 10.1097/QAI.0000000000001945 10.1097/QAD.0b013e32833fb71f 10.1007/s40519-021-01222-4 10.1056/NEJMoa2101016 10.1007/s10461-022-03658-w 10.2105/AJPH.2011.300530 10.1080/09540121.2018.1557590 10.1177/1359105307076232 10.1038/s41598-023-32014-8 10.2105/AJPH.2009.168971 10.4135/9781412986274 10.1136/bmjopen-2017-019701 10.1097/QAI.0000000000000212 10.1038/s41598-021-01634-3 10.1002/jia2.25528 10.1016/j.eclinm.2022.101507 10.1016/S2352-3018(20)30203-4 10.1037/0022-006X.73.3.477 10.1016/S2352-3018(23)00079-6 10.1089/aid.2017.0224 10.1007/s10461-016-1606-4 10.1007/978-3-030-04342-1_5 10.1056/NEJMoa1402269 10.1007/s12325-020-01295-0 10.1007/s10461-020-03023-9 10.1016/S1077-7229(99)80052-2 |
| ContentType | Journal Article |
| Copyright | 2024 The Author(s). published by John Wiley & Sons Ltd on behalf of International AIDS Society. 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. COPYRIGHT 2024 John Wiley & Sons, Inc. 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2024 The Author(s). published by John Wiley & Sons Ltd on behalf of International AIDS Society. – notice: 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. – notice: COPYRIGHT 2024 John Wiley & Sons, Inc. – notice: 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| CorporateAuthor | HPTN 083‐02 Study Team the HPTN 083‐02 Study Team |
| CorporateAuthor_xml | – sequence: 0 name: the HPTN 083‐02 Study Team – name: HPTN 083‐02 Study Team |
| DBID | 24P WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 DOA |
| DOI | 10.1002/jia2.26252 |
| DatabaseName | Wiley Open Access Wiley Online Library Free Content Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Publicly Available Content (ProQuest) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) Coronavirus Research Database ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley_OA刊 url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health Education |
| EISSN | 1758-2652 |
| EndPage | n/a |
| ExternalDocumentID | oai_doaj_org_article_98512b389e2b4527adca150c40933567 A797138548 10_1002_jia2_26252 38783534 JIA226252 |
| Genre | article Journal Article |
| GeographicLocations | Brazil South Africa United States Illinois Atlanta Georgia Rio de Janeiro Brazil Chicago Illinois United States--US |
| GeographicLocations_xml | – name: Brazil – name: South Africa – name: United States – name: Illinois – name: Atlanta Georgia – name: Rio de Janeiro Brazil – name: United States--US – name: Chicago Illinois |
| GrantInformation_xml | – fundername: National Institute on Drug Abuse – fundername: Eunice Kennedy Shriver Institute for Child Health and Human Development funderid: UM1AI068619 – fundername: National Institute of Allergy and Infectious Diseases – fundername: National Institute of Mental Health – fundername: HPTN Statistical and Data Management Center funderid: UM1AI068613 – fundername: National Institutes of Health – fundername: HIV Prevention Trials Network funderid: UM1AI068617 – fundername: HIV Prevention Trials Network grantid: UM1AI068617 – fundername: HPTN Statistical and Data Management Center grantid: UM1AI068613 – fundername: NIDA NIH HHS – fundername: Eunice Kennedy Shriver Institute for Child Health and Human Development grantid: UM1AI068619 – fundername: NIH HHS – fundername: NIMH NIH HHS |
| GroupedDBID | --- -5E -5G -BR 0R~ 1OC 24P 29L 2VQ 2WC 3V. 4.4 53G 5GY 5VS 7X7 88E 8FI 8FJ AAHHS ABDBF ABUWG ACCFJ ACGFO ACGFS ACRMQ ACXQS ADBBV ADINQ ADKYN ADPDF ADRAZ ADUKV ADZMN AEEZP AEGXH AENEX AEQDE AFGXO AFKRA AHBYD AHMBA AIAGR AIWBW AJBDE ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMKLP AOIJS AVUZU BAWUL BCNDV BENPR BMC BPHCQ BVXVI C24 C6C CCPQU DIK E3Z EBD EBS EJD EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO ICW IEA IHR IHW INH INR IOF ITC KQ8 M1P M48 M~E N8Y O5R O5S O9- OK1 OVD OVEED P2P PIMPY PQQKQ PROAC PSQYO RNS ROL RPM RSV SMD SOJ SV3 TEORI TR2 TUS UKHRP WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION 7XB 8FK AZQEC COVID DWQXO K9. PQEST PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c5542-1cc0214d48fbc24a24dd7c8c3cf11dcfede93e152618fa3037429c1cc57e6b163 |
| IEDL.DBID | DOA |
| ISSN | 1758-2652 |
| IngestDate | Tue Oct 22 14:47:14 EDT 2024 Sat Oct 26 02:58:13 EDT 2024 Thu Oct 10 15:23:36 EDT 2024 Tue Nov 19 21:34:22 EST 2024 Wed Nov 13 05:20:29 EST 2024 Tue Nov 12 23:38:20 EST 2024 Tue Aug 20 22:14:20 EDT 2024 Fri Dec 06 01:25:17 EST 2024 Sat Nov 02 12:30:58 EDT 2024 Sat Aug 24 00:58:59 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | pre‐exposure prophylaxis HIV prevention qualitative injectable PrEP men who have sex with men transgender women |
| Language | English |
| License | Attribution 2024 The Author(s). Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5542-1cc0214d48fbc24a24dd7c8c3cf11dcfede93e152618fa3037429c1cc57e6b163 |
| Notes | Clinical Trial Number: NCT02720094 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-7154-8151 0000-0002-9404-4455 0000-0001-5862-6530 0000-0002-0121-0806 0000-0002-0036-3165 0000-0003-1749-023X 0000-0001-7022-8332 0000-0002-0705-2239 0000-0001-5611-0119 |
| OpenAccessLink | https://doaj.org/article/98512b389e2b4527adca150c40933567 |
| PMID | 38783534 |
| PQID | 3060796386 |
| PQPubID | 55048 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_98512b389e2b4527adca150c40933567 proquest_miscellaneous_3060379388 proquest_journals_3060796386 gale_infotracmisc_A797138548 gale_infotracgeneralonefile_A797138548 gale_infotracacademiconefile_A797138548 gale_healthsolutions_A797138548 crossref_primary_10_1002_jia2_26252 pubmed_primary_38783534 wiley_primary_10_1002_jia2_26252_JIA226252 |
| PublicationCentury | 2000 |
| PublicationDate | May 2024 2024-May 2024-05-00 20240501 2024-05-01 |
| PublicationDateYYYYMMDD | 2024-05-01 |
| PublicationDate_xml | – month: 05 year: 2024 text: May 2024 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Geneva |
| PublicationTitle | Journal of the International AIDS Society |
| PublicationTitleAlternate | J Int AIDS Soc |
| PublicationYear | 2024 |
| Publisher | John Wiley & Sons, Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley |
| References | 2021; 25 2023; 76 2023; 10 2021; 21 2023; 13 2012; 102 2019; 31 2022; 51 2019; 35 2017; 21 1998 2010; 100 2020; 37 2022; 26 2012; 18 2021; 385 2002 2022; 22 2012; 367 1999; 6 2007; 12 2022; 27 2014; 66 2015; 372 2020; 7 2019; 80 2018; 8 2021; 11 2010; 24 2005; 73 2019 2020; 23 2020; 66 e_1_2_12_4_1 e_1_2_12_3_1 e_1_2_12_6_1 e_1_2_12_19_1 e_1_2_12_18_1 e_1_2_12_2_1 e_1_2_12_17_1 e_1_2_12_16_1 e_1_2_12_20_1 e_1_2_12_21_1 e_1_2_12_22_1 e_1_2_12_23_1 e_1_2_12_24_1 e_1_2_12_25_1 e_1_2_12_26_1 Scheurer D (e_1_2_12_33_1) 2012; 18 Antonini M (e_1_2_12_5_1) 2023; 76 e_1_2_12_27_1 e_1_2_12_28_1 e_1_2_12_29_1 e_1_2_12_30_1 e_1_2_12_31_1 e_1_2_12_32_1 e_1_2_12_34_1 e_1_2_12_35_1 e_1_2_12_36_1 e_1_2_12_15_1 e_1_2_12_14_1 e_1_2_12_13_1 e_1_2_12_8_1 e_1_2_12_11_1 Strauss A (e_1_2_12_12_1) 1998 e_1_2_12_7_1 e_1_2_12_10_1 e_1_2_12_9_1 |
| References_xml | – volume: 385 start-page: 595 year: 2021 end-page: 608 article-title: Cabotegravir for HIV prevention in cisgender men and transgender women publication-title: N Engl J Med – volume: 76 year: 2023 article-title: Barriers to pre‐exposure prophylaxis (PrEP) use for HIV: an integrative review publication-title: Rev Bras Enferm – volume: 27 start-page: 813 year: 2022 end-page: 820 article-title: Sexual and gender minority individuals report higher rates of lifetime traumas and current PTSD than cisgender heterosexual individuals admitted to residential eating disorder treatment publication-title: Eat Weight Disord – volume: 37 start-page: 1778 year: 2020 end-page: 1811 article-title: Barriers to the wider use of pre‐exposure prophylaxis in the United States: a narrative review publication-title: Adv Ther – start-page: 85 year: 2019 end-page: 105 – volume: 51 year: 2022 article-title: Preferences for pre‐exposure prophylaxis for HIV: a systematic review of discrete choice experiments publication-title: eClinicalMedicine – volume: 26 start-page: 3079 year: 2022 end-page: 3087 article-title: Barriers to oral HIV pre‐exposure prophylaxis (PrEP) adherence among pregnant and post‐partum women from Cape Town, South Africa publication-title: AIDS Behav – volume: 13 start-page: 5116 year: 2023 article-title: Exploring preferences and decision‐making about long‐acting injectable HIV pre‐exposure prophylaxis (PrEP) among young sexual minority men 17–24 years old publication-title: Sci Rep – volume: 23 year: 2020 article-title: Preferences for long‐acting pre‐exposure prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment publication-title: J Int AIDS Soc – volume: 66 start-page: 268 year: 2020 end-page: 274 article-title: Social support networks among young men and transgender women of color receiving HIV pre‐exposure prophylaxis publication-title: J Adolesc Health – volume: 24 start-page: 2717 year: 2010 end-page: 2725 article-title: Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study publication-title: AIDS – volume: 6 start-page: 332 year: 1999 end-page: 341 article-title: Life‐steps: applying cognitive behavioral therapy to HIV medication adherence publication-title: Cogn Behav Pract – volume: 80 start-page: 394 year: 2019 end-page: 403 article-title: Young women's stated preferences for biomedical HIV prevention: results of a discrete choice experiment in Kenya and South Africa publication-title: J Acquir Immune Defic Syndr – volume: 35 start-page: 100 year: 2019 end-page: 107 article-title: Indirect benefits in HIV cure clinical research: a qualitative analysis publication-title: AIDS Res Hum Retroviruses – volume: 21 start-page: 1350 year: 2017 end-page: 1360 article-title: Optimizing pre‐exposure antiretroviral prophylaxis adherence in men who have sex with men: results of a pilot randomized controlled trial of “Life‐Steps for PrEP publication-title: AIDS Behav – year: 1998 – volume: 8 year: 2018 article-title: What are healthcare providers’ understandings and experiences of compassion? The healthcare compassion model: a grounded theory study of healthcare providers in Canada publication-title: BMJ Open – volume: 25 start-page: 667 year: 2021 end-page: 678 article-title: Interest in long‐acting injectable pre‐exposure prophylaxis (LAI PrEP) among women in the Women's Interagency HIV Study (WIHS): a qualitative study across six cities in the United States publication-title: AIDS Behav – volume: 21 start-page: e645 year: 2021 end-page: e647 article-title: The unspoken benefit of participation in a clinical trial publication-title: Clin Med – volume: 12 start-page: 444 year: 2007 end-page: 460 article-title: Treatment adherence among primary care patients in a historically disadvantaged community in South Africa: a qualitative study publication-title: J Health Psychol – volume: 66 start-page: 522 year: 2014 end-page: 529 article-title: An intervention to support HIV preexposure prophylaxis adherence in HIV‐serodiscordant couples in Uganda publication-title: J Acquir Immune Defic Syndr – volume: 367 start-page: 411 year: 2012 end-page: 422 article-title: Preexposure prophylaxis for HIV infection among African women publication-title: N Engl J Med – volume: 100 start-page: 2433 year: 2010 end-page: 2441 article-title: Pervasive trauma exposure among US sexual orientation minority adults and risk of posttraumatic stress disorder publication-title: Am J Public Health – year: 2002 – volume: 10 start-page: e404 year: 2023 end-page: e411 article-title: The future of HIV pre‐exposure prophylaxis adherence: reducing barriers and increasing opportunities publication-title: Lancet HIV – volume: 372 start-page: 509 year: 2015 end-page: 518 article-title: Tenofovir‐based preexposure prophylaxis for HIV infection among African women publication-title: N Engl J Med – volume: 18 start-page: e461 year: 2012 end-page: e467 article-title: Association between different types of social support and medication adherence publication-title: Am J Manag Care – volume: 7 start-page: e721 year: 2020 end-page: e730 article-title: Initiation, discontinuation, and restarting HIV pre‐exposure prophylaxis: ongoing implementation strategies publication-title: Lancet HIV – volume: 22 start-page: 1728 year: 2022 article-title: Zero knowledge and high interest in the use of long‐acting injectable pre‐exposure prophylaxis (PrEP) among adolescent men who have sex with men and transgender women in two capital cities in Brazil publication-title: BMC Public Health – volume: 11 year: 2021 article-title: Preferences regarding emerging HIV prevention technologies among Toronto men who have sex with men: a discrete choice experiment publication-title: Sci Rep – volume: 26 start-page: 3099 year: 2022 end-page: 3109 article-title: HIV pre‐exposure prophylaxis implant stated preferences and priorities: results of a discrete choice experiment among women and adolescent girls in Gauteng Province, South Africa publication-title: AIDS Behav – volume: 102 start-page: 1587 year: 2012 end-page: 1593 article-title: Elevated risk of posttraumatic stress in sexual minority youths: mediation by childhood abuse and gender nonconformity publication-title: Am J Public Health – volume: 73 start-page: 477 year: 2005 end-page: 487 article-title: Victimization over the life span: a comparison of lesbian, gay, bisexual, and heterosexual siblings publication-title: J Consult Clin Psychol – volume: 31 start-page: 545 year: 2019 end-page: 553 article-title: Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment publication-title: AIDS Care – ident: e_1_2_12_13_1 – ident: e_1_2_12_25_1 doi: 10.1186/s12889-022-14134-4 – ident: e_1_2_12_3_1 doi: 10.1056/NEJMoa1202614 – ident: e_1_2_12_34_1 doi: 10.1016/j.jadohealth.2019.08.014 – ident: e_1_2_12_6_1 doi: 10.1007/s10461-022-03652-2 – volume-title: Basics of qualitative research: procedures and techniques for developing grounded theory year: 1998 ident: e_1_2_12_12_1 contributor: fullname: Strauss A – ident: e_1_2_12_21_1 doi: 10.7861/clinmed.2021-0292 – ident: e_1_2_12_16_1 doi: 10.1097/QAI.0000000000001945 – ident: e_1_2_12_36_1 doi: 10.1097/QAD.0b013e32833fb71f – ident: e_1_2_12_30_1 doi: 10.1007/s40519-021-01222-4 – ident: e_1_2_12_2_1 doi: 10.1056/NEJMoa2101016 – volume: 18 start-page: e461 year: 2012 ident: e_1_2_12_33_1 article-title: Association between different types of social support and medication adherence publication-title: Am J Manag Care contributor: fullname: Scheurer D – ident: e_1_2_12_18_1 doi: 10.1007/s10461-022-03658-w – ident: e_1_2_12_29_1 doi: 10.2105/AJPH.2011.300530 – ident: e_1_2_12_14_1 doi: 10.1080/09540121.2018.1557590 – ident: e_1_2_12_35_1 doi: 10.1177/1359105307076232 – ident: e_1_2_12_23_1 doi: 10.1038/s41598-023-32014-8 – ident: e_1_2_12_28_1 doi: 10.2105/AJPH.2009.168971 – ident: e_1_2_12_11_1 doi: 10.4135/9781412986274 – ident: e_1_2_12_31_1 doi: 10.1136/bmjopen-2017-019701 – ident: e_1_2_12_9_1 doi: 10.1097/QAI.0000000000000212 – ident: e_1_2_12_15_1 doi: 10.1038/s41598-021-01634-3 – ident: e_1_2_12_17_1 doi: 10.1002/jia2.25528 – ident: e_1_2_12_19_1 doi: 10.1016/j.eclinm.2022.101507 – ident: e_1_2_12_22_1 doi: 10.1016/S2352-3018(20)30203-4 – ident: e_1_2_12_27_1 doi: 10.1037/0022-006X.73.3.477 – ident: e_1_2_12_7_1 doi: 10.1016/S2352-3018(23)00079-6 – ident: e_1_2_12_20_1 doi: 10.1089/aid.2017.0224 – volume: 76 year: 2023 ident: e_1_2_12_5_1 article-title: Barriers to pre‐exposure prophylaxis (PrEP) use for HIV: an integrative review publication-title: Rev Bras Enferm contributor: fullname: Antonini M – ident: e_1_2_12_10_1 doi: 10.1007/s10461-016-1606-4 – ident: e_1_2_12_26_1 doi: 10.1007/978-3-030-04342-1_5 – ident: e_1_2_12_4_1 doi: 10.1056/NEJMoa1402269 – ident: e_1_2_12_8_1 doi: 10.1007/s12325-020-01295-0 – ident: e_1_2_12_24_1 doi: 10.1007/s10461-020-03023-9 – ident: e_1_2_12_32_1 doi: 10.1016/S1077-7229(99)80052-2 |
| SSID | ssj0062849 |
| Score | 2.3868933 |
| Snippet | Introduction
HPTN 083 demonstrated the superiority of long‐acting cabotegravir (CAB‐LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC)... HPTN 083 demonstrated the superiority of long-acting cabotegravir (CAB-LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) as... Introduction: HPTN 083 demonstrated the superiority of long‐acting cabotegravir (CAB‐LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate... HPTN 083 demonstrated the superiority of long‐acting cabotegravir (CAB‐LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) as... IntroductionHPTN 083 demonstrated the superiority of long-acting cabotegravir (CAB-LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC)... Abstract Introduction HPTN 083 demonstrated the superiority of long‐acting cabotegravir (CAB‐LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate... |
| SourceID | doaj proquest gale crossref pubmed wiley |
| SourceType | Open Website Aggregation Database Index Database Publisher |
| StartPage | e26252 |
| SubjectTerms | Adult Analysis Anti-HIV Agents - administration & dosage Anti-HIV Agents - therapeutic use Biological products industry Brazil Cisgender Demographics Diketopiperazines Disease prevention Education Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - administration & dosage Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - therapeutic use Ethnicity Female Gender identity Hispanic Americans HIV HIV Infections - drug therapy HIV Infections - prevention & control HIV prevention Homosexuality, Male Human immunodeficiency virus Humans injectable PrEP Injection Injections Interviews Interviews as Topic Male Marital status Medication Adherence - statistics & numerical data men who have sex with men Middle Aged Pre-Exposure Prophylaxis - methods Prevention pre‐exposure prophylaxis Prophylaxis Pyridines - administration & dosage Pyridines - therapeutic use Pyridones - administration & dosage Pyridones - therapeutic use qualitative Sexually transmitted diseases Sociodemographics STD Tenofovir - administration & dosage Tenofovir - therapeutic use Transgender people Transgender persons Transgender Persons - psychology transgender women Young Adult |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED9B94KEJhhfgQFGIJCQwho7Hw4vqEOdyiSqCm3S3izHdsp4SLas-_-5i92waGhvVXxJU9-Hf776fgfwwTg91S7J0NNcHaeVdnGJ_h0Tt1Mu0aRqTgXOP5f54jQ9PsvOQsLtKhyr3MbEPlDb1lCO_ACh7bQga8m_XVzG1DWK_l0NLTTuww5PhJQT2DmcL1e_trE4x-BbDqSk_ODPueZfOEJ-PlqGerb-2zH5xqJ0E7j2K8_RI9gNkJHNvI4fwz3X7FG35XAyYw8e-twb8yVFT2C9WJ0sGaKeeMq_stBRh52HdiS4VjFtf_syP7ZpcYByMVRCxVbdfMV0Y1lHWJqejqN44ZZMz0r7FE6P5iffF3FoqBAbRA08TowhijSbyroyPNU8tbYw0ghTJ4k1tbOuFKg43FXJWguipuGlwbuywuUVIrdnMGnaxr0AJirc2nCpRZoRKXtWWiFKJzNLeko4j-D9dn7VhefNUJ4hmSvSguq1EMEhTf0gQVzX_YW2W6vgOqpEUMgrBFaOV_hVhbZGI4w1KSVjsryI4C0pTvnC0cFj1awocQcucUsWwadegnx202mjQ-kB_hRivxpJfhxJrj339_8E90eC6JRmPLy1IhWCwpX6Z8IRvBuG6U466Na49trLCIyZEh_x3FvfMDtCUppOpBF87s3xjolVxz9mvP_08u43eQUPOMI0f4RzHyab7tq9Rpi1qd4EX_oLgAshcg priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1fa9RAEB9K-yKIWP9Gq64oCkJqb3eTbASRU1rOQss99KBvy2Z3U6-UnMYr6Jsfwc_oJ3FmNxcutPjk25Gd5MjszOxvNju_AXhpvdkzfpShp_k6lZXxaYn-nRK3U67QpGpOBc5Hx_lkJg9Ps9MNWPXv7BT4_drUjvpJzdqL3R_ffn5Ah3_fEYi-PZ8bvssRyGMo3uK4ItLRriPZf03IMQSXPTXpuvxgMQqc_Vcj89rStA5fw_pzcBtudcCRjeNMb8OGb-7AzbjrxmIx0V2YT6Ynxwzxzp9fv_f4O9Z102HzrhUJrlPMuC-xxI8tFzhA-zBUPsWm7f6UmcaxlnA0zReO4oUrMoGR9h7MDvZPPk3SrplCahEx8HRkLdGjOanqynJpuHSusMoKW49Gztbe-VLgpGFGpWojiJaGlxbvygqfV4ja7sNms2j8Q2CiwrSGKyNkRoTsWemEKL3KnCByF84TeLHSqv4aOTN0ZEfmmnSvg-4T-EgK7yWI5zpcWLRnunMbXSIg5BWCKs8r_KvCOGsQwlpJGzFZXiTwjKZLx6LR3lv1uCgx-1aYjiXwOkiQBS1bY01XdoCvQsxXA8lXA8mzyPt9neDOQBAd0g6HV7ajV_asSTUFBbs8gef9MN1Jh9wav7iMMgLjpcJHPIg212tHKNqiEzKBN8EI_6FYffh5zMOvR_9DxY_hBkcgFw957sDmsr30TxCILaunwcv-AqoBLEE priority: 102 providerName: Scholars Portal – databaseName: Wiley Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3faxQxEA6lfRFE6u-tVSOKgrC2N0l2s-LLKS1nwXIPLfQtZJNsPR_2ZHt990_wb_Qv6Uyyt-1SEXw7Nl_uuMnM5Muw84WxNy7YfRsmCiMtNLmsbcgrjO-ctJ0KjS7VADU4fzsuZqfy6EydbbBP616YpA8xFNwoMmK-pgC39cXetWjoj4WFD4D0HRPwFvKagu4vADlf5-ECE28V2yEV-kKhYBAnhb3ruaPtKKr2387NNzanmwQ27kCH2-xeTx35NK31fbYR2gfsbqq78dRO9JAtZvOTY46M58-v3_vwkff36fBFfxkJ7lTc-u-pyY-vljhAlRhqoOLz7mDObet5R0yaVgxH8cEtTNSkfcRODw9Ovszy_jqF3CFngHziHAmkeamb2oG0IL0vnXbCNZOJd03woRK4bHim0o0VJEwDlcNZqgxFjbztMdtsl214yrio8WAD2gqpSJJdVV6IKmjlBcm7AGTs9dqq5mdSzTBJHxkM2d5E22fsMxl8QJDSdXyw7M5NHzimQkoINdKqADX-VGm9s0hinaRSjCrKjL2k5TKpbXSIVzMtKzx_azyQZexdRFDErjrrbN94gH-FtK9GyLcj5HlS_v4bcHcExJB04-G175g-JVwYMk1J6a7I2KthmGbSa25tWF4mjMCMqfErniSfG6wjNBXphMzY--iE_zCsOfo6hfhp53_Az9gdQMqWXufcZZur7jI8R8q1ql_EyLoChyMgbA priority: 102 providerName: Wiley-Blackwell |
| Title | HPTN 083‐02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjia2.26252 https://www.ncbi.nlm.nih.gov/pubmed/38783534 https://www.proquest.com/docview/3060796386 https://www.proquest.com/docview/3060379388 https://doaj.org/article/98512b389e2b4527adca150c40933567 |
| Volume | 27 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1fb9MwELdgvCAhxH8yRjECgYSUrT07icNbNzp1k1YitE4VL5ZjO9A9pKh073wEPiOfhLs4rRoNwQsvSRVfqvbOd_c7y_czY6-tN33jBwl6mq9iWRof5-jfMXE7pQqnVAXU4Hw2ScdTeTpLZltHfdGesEAPHBR3kCMkgBLTqodSJpAZZw2CGCupFE_S0Efeh3UxFWJwikE335CRwsHl3MA-INSHTvppWPqvx-KtZLQNWJuMc3yP3W2hIh-Gn3if3fD1A3YnrLPx0D70kM3HxfmEI8L59eNnH97z9vwcPm8PH8HMxI37Gpr6-GqBA7TyQg1TvFiOCm5qx5eEnMlCOIoPrsk0HLSP2PR4dH40jtvjE2KLGAHigbVEiOakqkoL0oB0LrPKClsNBs5W3vlcoJmwhlKVEUREA7nFt5LMpyXitMdsp17U_injosRCBpQRMiEK9iR3QuReJU4QnQtAxF6ttaq_BZYMHfiQQZPudaP7iB2SwjcSxGzdPEB769be-l_2jtgLMpcObaIb_9TDLMd6W2EBFrG3jQR56GpprGkbDfCvENdVR_JNR_JLYPr-k-BeRxBd0HaH13NHtyHguybVZBTe0oi93AzTm7StrfaLqyAjMEIq_IonYc5ttCMULcoJGbF3zST8i2L16ckQmk-7_0PFz9htQOgWtnXusZ3V8so_R-i1KnvsJsgCr9ks67Fbw4vp5yneD0eT4hPejz5enHzoNZ6I1zOpfgMDTiyl |
| link.rule.ids | 314,780,784,864,2102,2221,11562,12056,21388,24318,27924,27925,31719,31720,33744,33745,38516,43310,43805,43895,46052,46476,50814,50923,73745,74302,74412 |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED9B9wASQjC-AoMZgUBCytbY-eQFdahTN7aqQp20N8uxnTIekpF1_z93sRsWDe2tii9p6vvwz1ff7wA-aqvGykYJepqtwrhUNizQv0PidkpzNKmKU4Hz6TydncXH58m5T7hd-WOVm5jYBWrTaMqR7yO0HWdkLem3yz8hdY2if1d9C437sEXM6ckItg6m88XPTSxOMfgWPSkp3_99ofgeR8jPB8tQx9Z_OybfWJRuAtdu5Tl8Ao89ZGQTp-OncM_W29Rt2Z_M2IZHLvfGXEnRM1jNFss5Q9QTjvlX5jvqsAvfjgTXKqbML1fmx9YNDlAuhkqo2KKdLpiqDWsJS9PTcRQv3JLpWGmfw9nhdPl9FvqGCqFG1MDDSGuiSDNxXpWax4rHxmQ610JXUWR0ZY0tBCoOd1V5pQRR0_BC411JZtMSkdsLGNVNbV8BEyVubXiuRJwQKXtSGCEKmyeG9BRxHsCHzfzKS8ebIR1DMpekBdlpIYADmvpegriuuwtNu5LedWSBoJCXCKwsL_GrMmW0QhirY0rGJGkWwC4pTrrC0d5j5SQrcAee45YsgM-dBPnsulVa-dID_CnEfjWQ_DSQXDnu7_8J7gwE0Sn1cHhjRdIHhSv5z4QDeN8P05100K22zbWTERgzc3zES2d9_eyInNJ0Ig7gS2eOd0ysPD6a8O7T67vfZBcezJanJ_LkaP7jDTzkCNnccc4dGK3ba_sWIde6fOf96i8qMSRa |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED9BJyEkhGB8BQYzAoGEFNrY-eQFddCqG1BVaJP2Zjm2U8ZDMrLu_-cudsOiob1V8SVNfR_-2b37HcBbbdVE2ShBT7NVGJfKhgX6d0jcTmmOJlVxKnD-sUwXJ_HRaXLq858ufFrlNiZ2gdo0ms7IxwhtJxlZSzqufFrE6uv88_mfkDpI0T-tvp3GbdjBVXHCR7BzMFuufm7jcoqBuOgJSvn495niHznCfz5Ykjrm_uvx-coCdRXEdqvQ_AHc9_CRTZ2-H8ItW-9S52WfpbEL99w5HHPlRY9gvVgdLxkioHDCPzHfXYed-dYkuG4xZX65kj-2aXCAzmWonIqt2tmKqdqwlnA1PR1H8cI1mY6h9jGczGfHXxahb64QakQQPIy0Jro0E-dVqXmseGxMpnMtdBVFRlfW2EKgEnGHlVdKEE0NLzTelWQ2LRHFPYFR3dT2GTBR4jaH50rECRG0J4URorB5YkhnEecBvNnOrzx3HBrSsSVzSVqQnRYCOKCp7yWI97q70LRr6d1IFggQeYkgy_ISvypTRiuEtDqmg5kkzQLYJ8VJV0Tae6-cZgXuxnPcngXwvpMg_920SitfhoA_hZiwBpLvBpJrxwP-P8G9gSA6qB4Ob61I-gBxIf-ZcwCv-2G6k5LeattcOhmB8TPHRzx11tfPjsjpyE7EAXzozPGGiZVHh1PefXp-85vswx10Kfn9cPntBdzliN5cZucejDbtpX2J6GtTvvJu9Rc1USiH |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HPTN+083%E2%80%9002%3A+factors+influencing+adherence+to+injectable+PrEP+and+retention+in+an+injectable+PrEP+study&rft.jtitle=Journal+of+the+International+AIDS+Society&rft.au=Christina+Psaros&rft.au=Georgia+R.+Goodman&rft.au=Jasper+S.+Lee&rft.au=Whitney+Rice&rft.date=2024-05-01&rft.pub=Wiley&rft.eissn=1758-2652&rft.volume=27&rft.issue=5&rft.epage=n%2Fa&rft_id=info:doi/10.1002%2Fjia2.26252&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_98512b389e2b4527adca150c40933567 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1758-2652&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1758-2652&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1758-2652&client=summon |